Ocuphire Pharma, through its subsidiary Opus Genetics, is at the forefront of developing innovative gene therapies aimed at treating inherited retinal diseases (IRDs) and other retinal disorders. The company employs a patient-guided approach to gene therapy, focusing on targeting specific genetic mutations that lead to vision loss. Their pipeline includes treatments for conditions such as bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa (RP). By concentrating on these genetic mutations, Opus Genetics aims to create effective therapies that not only preserve vision but also address a broader range of inherited blinding conditions.

The company’s unique strategy involves building a robust platform to efficiently develop solutions for various inherited retinal diseases. This approach is underscored by a commitment to advancing scientific research and collaboration, as evidenced by the involvement of experts like Dr. Jean Bennett, who emphasizes the importance of dedicated research in the field of blinding diseases. Opus Genetics is dedicated to providing hope and potential treatments for patients suffering from rare eye diseases, reflecting a strong mission to improve the quality of life for those affected by these conditions.

United States

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company developing and commercializing therapies for the treatment of eye disorders.

Opus Genetics (formerly Ocuphire Pharma)

Company Details